Study of Enzastaurin Versus Placebo With Pemetrexed for Participants With Advanced or Metastatic Lung Cancer

Completed · Phase 2 · Has a placebo group

Conditions studied: Non-small Cell Lung Cancer

In brief

The purpose of this study is to determine if the combination of enzastaurin and pemetrexed can extend survival time without progression of disease for participants who have advanced or metastatic non-small cell lung cancer (NSCLC).

Key facts

Study ID
NCT00530621
Run by
Eli Lilly and Company
People needed
160
Starts
2007-09-01
Expected to finish
2008-10-01
Last updated by the study team
2020-07-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.